VPAH.F Stock Overview
Volpara Health Technologies Limited provides breast imaging analytics software products in New Zealand.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Volpara Health Technologies Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.59 |
| 52 Week High | AU$0.89 |
| 52 Week Low | AU$0.41 |
| Beta | 1.68 |
| 1 Month Change | -18.84% |
| 3 Month Change | -22.04% |
| 1 Year Change | n/a |
| 3 Year Change | -40.75% |
| 5 Year Change | n/a |
| Change since IPO | 7.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| VPAH.F | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | -16.8% | -4.7% | -3.2% |
| 1Y | n/a | -13.6% | 19.3% |
Return vs Industry: Insufficient data to determine how VPAH.F performed against the US Healthcare Services industry.
Return vs Market: Insufficient data to determine how VPAH.F performed against the US Market.
Price Volatility
| VPAH.F volatility | |
|---|---|
| VPAH.F Average Weekly Movement | n/a |
| Healthcare Services Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VPAH.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine VPAH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 156 | Teri Thomas | www.volparahealth.com |
Volpara Health Technologies Limited provides breast imaging analytics software products in New Zealand. The company offers Volpara Analytics, a software that optimize breast cancer screening operations; Volpara Live, which provides instant patient-based image quality feedback; Volpara Lung, a patient management software that streamlines lung screening workflow; and Volpara Patient Hub, a customizable mammography reporting and patient communications software. It also offers Volpara Risk, an integration with Patient Hub that uses TC8 to calculate patients’ risk of developing breast cancer; Volpara Risk Pathways, a program for identifying and managing high-risk breast, lung, ovarian, and colorectal cancer screening patients; Volpara Scorecard, which displays patient breast density and risk insights essential for improved clinical decision-making and early detection; and Volpara Science, an AI-based software that powers Volpara software products; and Volpara Thumbnail, an image-enhanced patient notification letters.
Volpara Health Technologies Limited Fundamentals Summary
| VPAH.F fundamental statistics | |
|---|---|
| Market cap | US$187.03m |
| Earnings (TTM) | -US$5.28m |
| Revenue (TTM) | US$22.47m |
8.3x
P/S Ratio-35.4x
P/E RatioIs VPAH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VPAH.F income statement (TTM) | |
|---|---|
| Revenue | NZ$37.96m |
| Cost of Revenue | NZ$2.93m |
| Gross Profit | NZ$35.03m |
| Other Expenses | NZ$43.95m |
| Earnings | -NZ$8.92m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.035 |
| Gross Margin | 92.27% |
| Net Profit Margin | -23.50% |
| Debt/Equity Ratio | 0% |
How did VPAH.F perform over the long term?
See historical performance and comparison